Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions
Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions
复制标题
DOI：
10.1177/107327481201900305
复制
发表时间：
2012-07-01
期刊：
影响因子：
2.6
通讯作者：
Dalia, Samir M.
中科院分区：
文献类型：
--
作者：
Cultrera, Jennifer L.;Dalia, Samir M.
背景：弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤最常见的组织学类型，每年占新发病例的25% - 35%。在过去几十年中，DLBCL的发病率翻了一番，这凸显了对更有效治疗方案的需求。
方法：本文综述了适用于这种侵袭性淋巴瘤的现行治疗方案，并讨论了正在进行的侧重于分子诊断的研究，同时也明确了DLBCL的预后因素。
结果：DLBCL患者在临床表现、预后以及对现行治疗的反应方面存在差异。虽然利妥昔单抗时代的现行治疗已使疗效提高且毒性降低，但针对局限性、晚期以及复发/难治性DLBCL的新型治疗方法正在临床试验中进行探索。一些研究已显示出希望，例如涉及蛋白酶体抑制剂、来那度胺和抗体药物偶联物的试验。
结论：DLBCL患者治疗领域的近期发现促使个性化癌症医学和分子靶向治疗迎来复兴。潜在靶点和新型药物组合正在持续研究中，以期实现对该疾病的成功且个性化的治疗。
Background: DLBCL is the most common histology of non-Hodgkin lymphoma, representing 25% to 35% of new cases annually. The incidence of DLBCL has doubled in the past decades, highlighting the need for more effective treatment regimens.Methods: This article reviews the current protocols applicable to this aggressive lymphoma and discusses ongoing research that is focusing on molecular diagnostics, prognostic factors have also been defined for DLBCL.Results: Patients with DLBCL vary in clinical presentation, prognosis, and response to current therapies. While current therapy in the rituximab era has led to improved outcomes with reduced toxicity, novel treatment approaches for localized, advanced, and relapsed/refractory DLBCL are being pursued in clinical trials. Several studies have shown promise, such as trials involving proteasome inhibitors, lenalidomide, and antibody drug conjugates.Conclusions: Recent discoveries in the spectrum of care for patients with DLBCL have prompted a renaissance for personalized cancer medicine and molecularly targeted therapy. Potential targets and novel drug combinations are undergoing continued study in the hope of achieving successful and personalized care of this